Liya Wang, PhD

Principal Scientist
Merck & Co., Inc.,

Poster(s):

• (300) Economic burden of recurrence in early-stage hepatocellular carcinoma (HCC) treated with curative intent: A retrospective analysis of SEER-Medicare data
  Wednesday, October 29, 2025